Skip to main navigation Skip to search Skip to main content

Letter: Lebrikizumab for Refractory Atopic Dermatitis

Research output: Contribution to journal › Letter › peer-review

Original languageEnglish
JournalDermatitis
DOIs
StateAccepted/In press - 2025
Externally publishedYes

Cite this